CY1106682T1 - Ενωση λακταμης - Google Patents

Ενωση λακταμης

Info

Publication number
CY1106682T1
CY1106682T1 CY20071100848T CY071100848T CY1106682T1 CY 1106682 T1 CY1106682 T1 CY 1106682T1 CY 20071100848 T CY20071100848 T CY 20071100848T CY 071100848 T CY071100848 T CY 071100848T CY 1106682 T1 CY1106682 T1 CY 1106682T1
Authority
CY
Cyprus
Prior art keywords
laktamis
association
methods
methyl
alaninyl
Prior art date
Application number
CY20071100848T
Other languages
Greek (el)
English (en)
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1106682T1 publication Critical patent/CY1106682T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CY20071100848T 2000-11-17 2007-06-28 Ενωση λακταμης CY1106682T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (1)

Publication Number Publication Date
CY1106682T1 true CY1106682T1 (el) 2012-05-23

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100848T CY1106682T1 (el) 2000-11-17 2007-06-28 Ενωση λακταμης

Country Status (33)

Country Link
US (1) US20040248878A1 (enExample)
EP (1) EP1353910B1 (enExample)
JP (1) JP4116431B2 (enExample)
KR (1) KR20030045194A (enExample)
CN (2) CN100516047C (enExample)
AR (1) AR031356A1 (enExample)
AT (1) ATE362919T1 (enExample)
AU (2) AU2432102A (enExample)
BR (1) BR0115424A (enExample)
CA (1) CA2425497C (enExample)
CY (1) CY1106682T1 (enExample)
CZ (1) CZ20031340A3 (enExample)
DE (1) DE60128587T2 (enExample)
DK (1) DK1353910T3 (enExample)
DZ (1) DZ3454A1 (enExample)
EA (1) EA006919B1 (enExample)
EC (1) ECSP034598A (enExample)
ES (1) ES2286162T3 (enExample)
HR (1) HRP20030385A2 (enExample)
HU (1) HUP0301862A3 (enExample)
IL (1) IL155275A0 (enExample)
MX (1) MXPA03004250A (enExample)
MY (1) MY141607A (enExample)
NO (1) NO325217B1 (enExample)
PE (1) PE20020798A1 (enExample)
PL (1) PL211018B1 (enExample)
PT (1) PT1353910E (enExample)
SK (1) SK287794B6 (enExample)
SV (1) SV2003000741A (enExample)
TW (1) TWI235151B (enExample)
UA (1) UA77165C2 (enExample)
WO (1) WO2002040451A2 (enExample)
ZA (1) ZA200303411B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1867636B1 (en) 2005-04-08 2013-06-05 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
JP5198877B2 (ja) 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
IL296723A (en) 2020-03-26 2022-11-01 Seagen Inc Methods of treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2272305A1 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds as .beta.-amyloid peptide release inhibitors
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO2001034571A1 (en) * 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS

Also Published As

Publication number Publication date
WO2002040451A2 (en) 2002-05-23
US20040248878A1 (en) 2004-12-09
DZ3454A1 (fr) 2002-05-23
ECSP034598A (es) 2003-06-25
ZA200303411B (en) 2004-08-02
EP1353910B1 (en) 2007-05-23
PE20020798A1 (es) 2002-09-06
JP2004521084A (ja) 2004-07-15
UA77165C2 (en) 2006-11-15
AR031356A1 (es) 2003-09-17
ATE362919T1 (de) 2007-06-15
PL360991A1 (en) 2004-09-20
BR0115424A (pt) 2003-10-21
EA006919B1 (ru) 2006-04-28
EA200300579A1 (ru) 2003-12-25
TWI235151B (en) 2005-07-01
CN100516047C (zh) 2009-07-22
DK1353910T3 (da) 2007-09-10
PL211018B1 (pl) 2012-03-30
AU2002224321B2 (en) 2006-10-19
CA2425497C (en) 2010-08-17
SV2003000741A (es) 2003-01-13
HUP0301862A3 (en) 2007-09-28
CA2425497A1 (en) 2002-05-23
CZ20031340A3 (cs) 2004-06-16
PT1353910E (pt) 2007-08-20
DE60128587D1 (de) 2007-07-05
IL155275A0 (en) 2003-11-23
NO20032215L (no) 2003-07-16
HRP20030385A2 (en) 2003-08-31
DE60128587T2 (de) 2008-01-31
HUP0301862A2 (hu) 2003-09-29
WO2002040451A3 (en) 2003-08-28
CN1575282A (zh) 2005-02-02
NO325217B1 (no) 2008-02-25
CN101624372A (zh) 2010-01-13
SK287794B6 (sk) 2011-10-04
EP1353910A2 (en) 2003-10-22
MXPA03004250A (es) 2003-09-22
JP4116431B2 (ja) 2008-07-09
MY141607A (en) 2010-05-31
NO20032215D0 (no) 2003-05-15
ES2286162T3 (es) 2007-12-01
SK5432003A3 (en) 2004-09-08
KR20030045194A (ko) 2003-06-09
AU2432102A (en) 2002-05-27

Similar Documents

Publication Publication Date Title
CY1106682T1 (el) Ενωση λακταμης
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
CY1106467T1 (el) Ελεγχομενη συνθεση ζιπρασιδονης
BR9902086A (pt) Formulações farmacêuticas.
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
IT1317716B1 (it) Processo per la preparazione di perfluoropoliossialchileni conterminali ossidrilici.
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten
ATE391489T1 (de) Haarbehandlungszusammensetzungen
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
CY1105345T1 (el) Φαινυλαλκινια
DK1328275T3 (da) Substituerede 4,5-dihydro-1,2,4-triazin-3-oner, 1,2,4-triazin-3-oner og deres anvendelse som fungicider og insekticider
ITTO20030850A1 (it) Procedimento per la preparazione di 4-ammino-3,5-dicloro-benzotrifloruro.
ITTO20020744A1 (it) Composizione.
PT1408035E (pt) Metodo de preparacao de derivativos de 1.5-diaril-3-trifluorometilo-delta2-pirazolinas que sejam racemicos e enanciomericamente puros
CY1110737T1 (el) Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης